This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Alexza Pharma: FDA Panel Live Blog

BETHESDA, Md. (TheStreet) -- Alexza Pharmaceuticals (ALXA) is trying to convince an independent expert panel Monday that safety concerns focused on the risk of asthma-like side effects should not prevent the approval of its inhaled antipsychotic drug Adasuve.

Adasuve is a small, handheld device that delivers an inhaled dose of the antipsychotic drug loxapine into the lungs of patients. Adasuve is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.

The U.S. Food and Drug Administration rejected Alexza's Adasuve application in October 2010 primarily due to concerns that inhaling the drug caused bronchospasms, or asthma-like constrictions of the lungs, in some patients.

Alexza resubmitted Adasuve to FDA, which asked an advisory panel of independent experts to review the drug/device Monday. The panel will be voting on whether or not to recommend Adasuve's approval.

In its morning presentation, Alexza argued that Adasuve is effective in treating acute episodes of agitation in schizophrenia patients. The company believes using an inhaled antipsychotic could be a meaningful benefit for agitated patients who typically must be physically restrained and treated with injections.

Alexza proposed a risk management plan that would screen out patients with lung problems and monitor patients treated with Adasuve to manage any bronchospasms, if they occur.

FDA used its presentation time at Monday's panel to raise questions about the way Alexza studies Adasuve in its clinical trials. The agency's reviewers said patients in the Adasuve studies were carefully screened which means they may have been better suited for Adasuve than "real world" schizophrenia patients. The FDA also presented data highlighting the lung safety concerns attributable to Adasuve.

The expert panel will spend the bulk of the afternoon debating the safety of Adasuve and will ultimately vote on whether to recommend approval or not.

Alexza shares were halted for trading Monday at 62 cents. The stock fell sharply last Thursday after FDA released its Adasuve review.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,915.07 -70.54 -0.42%
S&P 500 1,964.68 -8.15 -0.41%
NASDAQ 4,396.2040 -22.83 -0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs